Qiagen N.V. (QGEN) Sunday announced the acquisition of the Enzyme Solutions Unit of Enzymatics. Financial terms of the transaction, which was completed in December 2014, were not disclosed.
Enzymatics, a privately-held U.S. company founded in 2006, commercializes a comprehensive portfolio of reagents that are estimated to be used in more than 80% of all global NGS sequencing reactions. These enzymes are key ingredients across the workflows of all commercially available sequencing solutions.
"Enzymatics has distinguished itself as a premier enabler of the emergence of affordable, widely usable NGS sequencing", said Peer M. Schatz, CEO of QIAGEN. "These solutions are a perfect fit with our leading offering of universal NGS products as well as with our strategy to develop integrated workflows that will help to drive the adoption of NGS in clinical healthcare."
Qiagen has acquired all assets relating to the Enzyme Solutions Unit of Enzymatics - including R&D, manufacturing, formulation, and analytical capabilities - which will further enhance the company's expertise in enzymology. Approximately 50 employees have joined Qiagen at the current Enzymatics site in Beverly, Massachusetts.
For 2015, Qiagen expects the acquired Enyzmatics activities to provide about $20 million of incremental sales and to be accretive by about $0.01 per share to adjusted earnings.
For comments and feedback contact: editorial@rttnews.com
Business News